Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

NCT ID: NCT01139346

Last Updated: 2012-07-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2012-04-30

Brief Summary

This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.

Conditions

Advanced Solid Tumors

Keywords

carcinoma; sarcoma; metastatic; solid tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

oral darinaparsin

open label, single arm, dose escalation

Group Type: EXPERIMENTAL

darinaparsin

Intervention Type: DRUG

dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.

Interventions

darinaparsin

dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.

Intervention Type: DRUG

Other Intervention Names

ZIO-101-C; S-dimethylarsino-glutathione; Zinapar (TM)

Eligibility Criteria

Inclusion Criteria

• Subjects with histological or cytological confirmation of advanced cancer (solid tumor) that is refractory to standard therapies for their condition;
• Men and women of ≥18 years of age;
• ECOG performance score ≤2
• Eligible subjects with solid tumors MUST have at least one measurable lesion as defined by RECIST 1.1 guidelines. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions MUST NOT have been in a previously irradiated field or injected with biological agents;
• Life expectancy ≥12 weeks;
• Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements, to be conducted <2 weeks prior to Baseline:

• Creatinine ≤1.5 × upper limit of normal (ULN) OR a calculated creatinine clearance ≥50 cc/min
• Total bilirubin ≤2 × ULN
• Alanine transaminase (ALT) and aspartate transaminase (AST)≤3 × ULN
• Granulocytes in peripheral blood ≥1 × 109/L, hemoglobin ≥10 g/dL, and platelets ≥50,000 /µL
• Adequate vascular access for repeated blood sampling;
• Men and women of childbearing potential must agree to use effective contraception from Screening through the duration of Study participation;
• Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee (IEC/IRB) having jurisdiction over the site.

Exclusion Criteria

• Arsenic allergy.
• New York Heart Association (NYHA) functional class ≥3 myocardial infarction (see Appendix 3) within 6 months.
• Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block (LBBB); or documented history of prolonged QTc.
• Pregnant and/or lactating women.
• Uncontrolled systemic infection (documented with microbiological studies).
• Metastatic brain or meningeal tumors.
• Patients with seizure disorder requiring medication (such as anti-epileptics)
• History of confusion or dementia or neurological condition that could mask a potential adverse response to the Study Drug, which may include transient ischemic attack, Parkinson's disease, thrombotic or hemorrhagic stroke, Alzheimer's, and other neurological disorders.
• Anticancer chemotherapy or immunotherapy during the study or within four weeks of Study entry (mitomycin C or nitrosureas should not be given within 6 weeks of Study entry)
• Radiotherapy during study or within 3 weeks of Study entry.
• Major surgery within 4 weeks of start of Study Drug dosing.
• Other Investigational drug therapy during this trial within four weeks prior to Study entry.
• History of invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
• Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of Study results.
• Any condition that is unstable or could jeopardize the safety of the patient and his/her compliance in the Study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alaunos Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan J. Lewis, MD, PhD

Role: STUDY_DIRECTOR

ZIOPHARM, Oncology, Inc.

Locations

Lafayette, Indiana, United States

Dallas, Texas, United States

Houston, Texas, United States

Countries

United States

Other Identifiers

SGC1004

Identifier Type: -

Identifier Source: org_study_id